Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib + PegIFN in Newly Diagnosed CML
NCT01725204Phase 2Completed
- Sponsor
- Norwegian University of Science and Technology
- Start
- Sep 2012
- Primary completion
- May 2016
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 3
01
Overview
A Phase 2 trial of peginterferon alfa-2b in chronic myeloid leukemia (CML), sponsored by Norwegian University of Science and Technology. Started Sep 2012; status: completed.
02
Drugs
peginterferon alfa-2b
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01725204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01725204.